Abstract:Background Inflammation is a driver of atherosclerosis, but inflammatory mediators are essential components of the immune response. AtheroVax targets only pathogenic forms of sTNFR2 while preserving the membrane-bound (wild-type) TNFR2 and its contributions to a non-pathogenic immune response. We hypothesize that the vaccine mediated clearance of sTNRF2 will be more specific and offers long-term treatment options. The aim of this study is to investigate the therapeutic effect of an sTNFR2-targeting peptide (14 amino acid) vaccine, AtheroVax, in a rat model of acetic acid-induced colitis. Methods Two studies were conducted. In the first study 100 male outbred white Wistar rats (age 8 weeks, weight ~250 g) were used to evaluate a subcutaneous (SQ) injections of human sTNFR2 peptide sequence. In the second study 80 rats were used to evaluate SQ injections of the rat sTNFR2 sequence. After the adaptation period, the animals were randomly divided into treatment groups. In study 1, group A (n = 30), phosphate-buffered saline (PBS), group B (n = 30), 25 μg of alum diluted in PBS, group C (n = 30), 25 μg of alum + 25 μg of peptide diluted in PBS, and group D (n = 10) no colitis controls. In study 2, group A (n = 25), phosphate-buffered saline (PBS), group B (n = 25), 25 μg of alum + 25 μg of rat sTNFR2 peptide, group C (n = 30), 25 μg of alum + 75 μg of rat sTNFR2 peptide, and group D (n = 5) no colitis controls. The animals were kept under standard vivarium conditions (temperature 22±2°C, relative humidity 50±5%, light/dark cycles 12 h/12 h). Animals were fed ad libitum standard laboratory chow and water under the supervision of trained personnel. Results The short 14 amino acid peptides administered prior to initiating colitis significantly improved the course of colitis in both studies by significantly (p<0.05) reducing weight loss, fever, bleeding and diarrhea, and disease severity as well as providing a survival benefit (p<0.05) in rats with colitis. AtheroVax also significantly (p<0.001) reduced serum levels of TNF-α and IL-6. Histopathology evaluation reveals preservation of colon cellular architecture in vaccinated animals in both studies. Immunohistochemistry and examination of spleen and lymph nodes provides supporting evidence of the vaccine protection from chronic inflammation. Conclusion Our studies have shown that AtheroVax may be an effective therapeutic candidate for reducing chronic inflammation. These pre-clinical findings will provide a basis to further evaluate this novel vaccine in follow-up pre-clinical studies. A vaccine limiting the progression of atherosclerosis will greatly contribute to the reduction in morbidity and mortality from cardiovascular disease.

Chicken Muscle Protein-Derived Peptide VVHPKESF Reduces TNFα-Induced Inflammation and Oxidative Stress by Suppressing TNFR1 Signaling in Human Vascular Endothelial Cells

Ginsenoside Rb1 Inhibits Tumor Necrosis Factor-Alpha-Induced Vascular Cell Adhesion Molecule-1 Expression in Human Endothelial Cells

S‐Allyl‐L‐Cysteine Sulfoxide Inhibits Tumor Necrosis Factor‐Alpha Induced Monocyte Adhesion and Intercellular Cell Adhesion Molecule‐1 Expression in Human Umbilical Vein Endothelial Cells

Protective Effect of Vitexin Against IL-17-Induced Vascular Endothelial Inflammation Through Keap1/Nrf2-Dependent Signaling Pathway

VF-4 and DR-8 Derived from Salted Egg White Inhibit Inflammatory Activity Via NF-B/PI3K-Akt/MAPK Signal Transduction Pathways in HT-29 Cells Induced by TNF-

The Protective Effects of Tripeptides VPP and IPP Against Small Extracellular Vesicles from Angiotensin II-Induced Vascular Smooth Muscle Cells Mediating Endothelial Dysfunction in Human Umbilical Vein Endothelial Cells.

(-)-7(S)-hydroxymatairesinol Protects Against Tumor Necrosis Factor-Α-mediated Inflammation Response in Endothelial Cells by Blocking the MAPK/NF-κB and Activating Nrf2/HO-1

Analysis of proteome and transcriptome of tumor necrosis factor alpha stimulated vascular smooth muscle cells with or without alpha lipoic acid

Astragalus Polysaccharides Suppress ICAM-1 and VCAM-1 Expression in TNF-α-treated Human Vascular Endothelial Cells by Blocking NF-κB Activation

The Peptide Lycosin-I Attenuates TNF-α-induced Inflammation in Human Umbilical Vein Endothelial Cells Via IκB/NF-κB Signaling Pathway

Anti-inflammatory Activity of Di-Peptides Derived from Ovotransferrin by Simulated Peptide-Cut in TNF-α-induced Caco-2 Cells

Chicken muscle hydrolysate reduces blood pressure in spontaneously hypertensive rats, upregulates ACE2, and ameliorates vascular inflammation, fibrosis, and oxidative stress

The Anti-Inflammatory Effect of Vasoactive Peptides from Soybean Protein Hydrolysates by Mediating Serum Extracellular Vesicles-Derived Mirna-19B/cyld/traf6 Axis in the Vascular Microenvironment of SHRs.

VH-4-A Bioactive Peptide from Soybean and Exercise Training Constrict Hypertension in Rats through Activating Cell Survival and AMPKα1, Sirt1, PGC1α, and FoX3α

Natural Compound Resveratrol Attenuates TNF-Alpha-Induced Vascular Dysfunction in Mice and Human Endothelial Cells: The Involvement of the NF-κB Signaling Pathway

Tnfsf15 Inhibits Vegf-Stimulated Vascular Hyperpermeability by Inducing Vegfr2 Dephosphorylation

Inhibitory Effects of Eicosapentaenoic Acid on Vascular Endothelial Growth Factor-Induced Monocyte Chemoattractant Protein-1, Interleukin-6, and Interleukin-8 in Human Vascular Endothelial Cells

Ovotransferrin Inhibits TNF-α Induced Inflammatory Response in Gastric Epithelial Cells Via MAPK and NF-κB Pathway.

Walnut peptide WEKPPVSH in alleviating oxidative stress and inflammation in lipopolysaccharide-activated BV-2 microglia via the Nrf2/HO-1 and NF-κB/p38 MAPK pathways

The flavonoid hydroxygenkwanin reduces inflammation and neointimal formation

AtheroVax: a peptide vaccine with a therapeutic effect in animal model of chronic inflammation